Sara Ansari, R.D. Registered Dietitian, Nutrition Consultant, and Prevent Health Coach joins Lisa and talks anout the biggest obstacles to healthy eating that people face during the holiday season, best tips and strategies to staying healthy while at a holiday party, things people can do to mentally prepare for the holidays, emotional and stress eating and more!  

Listen here.

SAN DIEGO, Dec. 19, 2013 – ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that Mark G. Foletta has been appointed to its Board of Directors. Mr. Foletta is a seasoned financial executive with over 30 yearsof corporate experience.  He was most recently senior vice president and Chief Financial Officer at Amylin Pharmaceuticals, Inc.  He joined Amylin in 2000 and served through its acquisition by Bristol-Myers Squibb forapproximately $7 billion in August 2012.  During his time at Amylin the company grew from 75 to over 1,300 employees and he was instrumental leading numerous strategic transactions with global pharmaceutical companies, as well as public and private financing transactions.  As chair of Amylin’s Operating Committee, he had responsibility for business planning, forecasting and assessing performance. He also participated in the commercial launch of three novel pharmaceutical products that generated annual revenues reaching over $700M. Prior to Amylin, Mr. Foletta worked 14 years at Intermark, Inc./Triton Group Ltd. where he served as senior vice president,Chief Financial Officer and Corporate Secretary.

Read more: http://viacyte.com/press-releases/viacyte-appoints-mark-foletta-former-cfo-of-amylin-to-its-board-of-directors/

MALVERN, Pa., Dec. 17, 2013 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the closing of its initial public offering of 7,150,000 shares of its common stock at a public offering price of$7.00 per share, before the underwriting discount and offering costs. As a result, aggregate net proceeds to TetraLogic, after the underwriting discount and offering costs, were approximately $43,100,000.

In addition, the underwriters have a 30-day option to purchase up to an additional 1,072,500 shares of common stock at the same price to cover over-allotments, if any.

Oppenheimer & Co. Inc., Guggenheim Securities, LLC and Needham & Company, LLC acted as joint book-running managers for the offering.

TetraLogic intends to use the net proceeds of its initial public offering to advance the clinical and pre-clinical development of birinapant, other development programs, working capital and general corporate purposes.

TetraLogic has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the common stock being sold in the offering. The registration statement was declared effective by the SEC onDecember 11, 2013.

Read more: http://ir.tetralogicpharma.com/releasedetail.cfm?ReleaseID=814450

GUEST MENTOR Andréa Mallard, Chief Brand Officer at Omada Health: As an entrepreneur, the problem with negative feedback of any kind is that it’s instantly personal: they might as well have called your newborn ugly.

What’s more, thanks to social media, would-be critics have the power to tell the whole world your newborn is ugly. But take heart: the very fact that the feedback loop has gone public (and will, on occasion, go viral) is a good thing. It gives any entrepreneur the unprecedented chance to learn, to adapt and ultimately to strengthen his or her brand – but only if you know how to deal with it.

Now, there are some obvious don’ts that should be clear to all by now (eg. don’t get defensive, don’t get sucked into a shouting match, don’t delete everything but the good stuff). But beyond not doing the patently wrong thing, consider five ways to really do the right thing – not just for your critics, but for your company.

Read more: http://blogs.wsj.com/accelerators/2013/12/13/andrea-mallard-adopt-the-tone-of-your-brand-but-remain-human/

REDWOOD CITY, Calif., Dec. 3, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED) and Celgene Corporation (Nasdaq:CELG) today announced an agreement to jointly develop and commercialize up to six anti-cancer stem cell (CSC) product candidates from OncoMed's biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4).

OncoMed will control and conduct initial clinical studies at which point Celgene has an option to license worldwide rights to up to six novel anti-CSC therapeutic candidates. OncoMed retains global co-development and U.S. co-commercialization rights for five of the six anti-CSC product candidates with 50/50 U.S. profit sharing, and royalties to be received in other territories. Celgene will also have research, development and commercialization rights to small molecule compounds in an undisclosed cancer stem cell pathway. 

Celgene obtains an exclusive option on one of OncoMed's most advanced clinical candidates, demcizumab, during or after the completion of certain future planned Phase II clinical trials to be conducted by OncoMed. Demcizumab is currently in three Phase Ib clinical studies in combination with standard-of-care therapeutics, including a trial in patients with first-line advanced pancreatic cancer. Subsequent to option exercise, the parties will co-develop demcizumab, sharing global development costs on a 1/3 OncoMed and 2/3 Celgene basis. The companies will co-commercialize demcizumab in the United States with 50/50 profit sharing. Outside the United States, Celgene would lead development and commercialization, with OncoMed eligible to receive milestones and tiered double-digit royalties on sales outside the United States.

Read more: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=810970

...One Bay Area–based company, Omada Health, is making strides in addressing the prediabetes epidemic. The Omada Health program, Prevent, is an online version of a 2002 government-financed project sponsored by the National Institutes of Health called the Diabetes Prevention Program, which found that behavioral weight-loss programs can be more effective at combating diabetes than medication.

“Our 16-week online program helps people with prediabetes lose weight and adopt sustainable, healthy lifestyle changes,” says Sean Duffy, CEO of Omada Health. “In our program, we match people into groups of about 12 and bring them through the curriculum with a professionally trained health coach and all sorts of amazing digital tools, like a wireless-enabled scale, a Wi-Fi, or Bluetooth-enabled scale that wirelessly obtains your weight and measurements from your scale and syncs it, allowing you to visualize your weight loss online or on your smartphone. The goal is to create an environment where participants feel guided, supported, and put on a path toward better health.”

Duffy says that Prevent’s core model is to work with employers and insurers to cover the cost of the program, approximately $120 per month for the four-month course, since many employers and insurers are interested in new solutions to help their employees or members live healthier lives.

Read more: http://www.eastbaymedicalguide.com/East-Bay-Medical-Guide/Annual-2014/The-Prediabetes-Wake-up-Call/